Napabucasin
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206601

CAS#: 83280-65-3

Description: Napabucasin, also known as BBI-608, is an orally available cancer cell stemness inhibitor with potential antineoplastic activity. Even though the exact target has yet to be fully elucidated, BBI608 appears to target and inhibit multiple pathways involved in cancer cell stemness. This may ultimately inhibit cancer stemness cell (CSC) growth as well as heterogeneous cancer cell growth. CSCs, self-replicating cells that are able to differentiate into heterogeneous cancer cells, appear to be responsible for the malignant growth, recurrence and resistance to conventional chemotherapies.


Chemical Structure

img
Napabucasin
CAS# 83280-65-3

Theoretical Analysis

MedKoo Cat#: 206601
Name: Napabucasin
CAS#: 83280-65-3
Chemical Formula: C14H8O4
Exact Mass: 240.04
Molecular Weight: 240.210
Elemental Analysis: C, 70.00; H, 3.36; O, 26.64

Price and Availability

Size Price Availability Quantity
10mg USD 90 Ready to ship
25mg USD 150 Ready to ship
50mg USD 250 Ready to ship
100mg USD 450 Ready to ship
200mg USD 750 Ready to ship
500mg USD 2650 Ready to ship
1g USD 3750 Ready to ship
2g USD 6250 Ready to ship
Bulk inquiry

Synonym: BBI608; BBI 608; BB-I608; Napabucasin

IUPAC/Chemical Name: 2-Acetylnaphtho[2,3-b]furan-4,9-dione

InChi Key: DPHUWDIXHNQOSY-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H8O4/c1-7(15)11-6-10-12(16)8-4-2-3-5-9(8)13(17)14(10)18-11/h2-6H,1H3

SMILES Code: O=C(C1=C2OC(C(C)=O)=C1)C3=C(C2=O)C=CC=C3

Appearance: Yellow solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target: Napabucasin is a STAT3 inhibitor which blocks stem cell activity.
In vitro activity: As shown in Figure 2A, napabucasin significantly decreased the viability of Huh7 and Hepa1-6 cells in a time- and concentration-dependent manner. Consistent with this, the proportion of napabucasin-treated cells in the G1-phase was significantly lower compared to that of the untreated controls, which corresponded to an increase in the G2/M-phase cells (P < 0.05; Figure 2B). Furthermore, the apoptosis rates in Huh7 cells increased to 11.11%, 14.38% and 62.99% respectively within 12 h of exposure to 1, 2 and 5 µM napabucasin (Figure 2C), and similar results were obtained with Hepa1-6 cells as well. Taken together, napabucasin inhibited HCC cell growth in a concentration-dependent manner by inducing apoptosis and G2/M-phase arrest. Reference: Front Pharmacol. 2020; 11: 597520. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744694/
In vivo activity: After injecting Napabucasin (10 mg/kg) for 1 month, the terminal mouse body weights were greatly reduced in the Napabucasin group compared with mice in the control group (Figure 4A). As shown in Figures 4B,C, the phosphorylation of STAT3 was obviously blocked after one-month of Napabucasin injections in this study’s immunofluorescence investigation. H&E staining shown that Napabucasin injection-induced bone loss in the femora (Figure 4D). Then this study assessed the bone mass of femora from mice injected with vehicle or Napabucasin by micro-CT. Parameters such as BMD (Figure 4G), BV/TV (Figure 4H), Tb.Th. (Figure 4I), and Tb.N. (Figure 4J) were apparently reduced after 1-month injections of Napabucasin, while Tb.Sp. (Figure 4K) increased. However, Ct.Th. (Figure 4L) did not differ in this experiment. These results implied that the STAT3 inhibitor Napabucasin decreased the bone mass of WT mice. Reference: Front Cell Dev Biol. 2021; 9: 648866. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014090/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 10.0 41.63

Preparing Stock Solutions

The following data is based on the product molecular weight 240.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Li Y, Han Q, Zhao H, Guo Q, Zhang J. Napabucasin Reduces Cancer Stem Cell Characteristics in Hepatocellular Carcinoma. Front Pharmacol. 2020 Dec 3;11:597520. doi: 10.3389/fphar.2020.597520. PMID: 33343368; PMCID: PMC7744694. 2. Schmidtova S, Dorssers LCJ, Kalavska K, Gillis AJM, Oosterhuis JW, Stoop H, Miklikova S, Kozovska Z, Burikova M, Gercakova K, Durinikova E, Chovanec M, Mego M, Kucerova L, Looijenga LHJ. Napabucasin overcomes cisplatin resistance in ovarian germ cell tumor-derived cell line by inhibiting cancer stemness. Cancer Cell Int. 2020 Aug 3;20:364. doi: 10.1186/s12935-020-01458-7. PMID: 32774158; PMCID: PMC7397611. 3. Huang X, Jin A, Wang X, Gao X, Xu H, Chung M, Dai Q, Yang Y, Jiang L. Napabucasin Induces Mouse Bone Loss by Impairing Bone Formation via STAT3. Front Cell Dev Biol. 2021 Mar 18;9:648866. doi: 10.3389/fcell.2021.648866. PMID: 33816498; PMCID: PMC8014090. 4. Leijten NM, Bakker P, Spaink HP, den Hertog J, Lemeer S. Thermal Proteome Profiling in Zebrafish Reveals Effects of Napabucasin on Retinoic Acid Metabolism. Mol Cell Proteomics. 2021 Feb 13;20:100033. doi: 10.1074/mcp.RA120.002273. Epub ahead of print. PMID: 33594990; PMCID: PMC7950114.
In vitro protocol: 1. Li Y, Han Q, Zhao H, Guo Q, Zhang J. Napabucasin Reduces Cancer Stem Cell Characteristics in Hepatocellular Carcinoma. Front Pharmacol. 2020 Dec 3;11:597520. doi: 10.3389/fphar.2020.597520. PMID: 33343368; PMCID: PMC7744694. 2. Schmidtova S, Dorssers LCJ, Kalavska K, Gillis AJM, Oosterhuis JW, Stoop H, Miklikova S, Kozovska Z, Burikova M, Gercakova K, Durinikova E, Chovanec M, Mego M, Kucerova L, Looijenga LHJ. Napabucasin overcomes cisplatin resistance in ovarian germ cell tumor-derived cell line by inhibiting cancer stemness. Cancer Cell Int. 2020 Aug 3;20:364. doi: 10.1186/s12935-020-01458-7. PMID: 32774158; PMCID: PMC7397611.
In vivo protocol: 1. Huang X, Jin A, Wang X, Gao X, Xu H, Chung M, Dai Q, Yang Y, Jiang L. Napabucasin Induces Mouse Bone Loss by Impairing Bone Formation via STAT3. Front Cell Dev Biol. 2021 Mar 18;9:648866. doi: 10.3389/fcell.2021.648866. PMID: 33816498; PMCID: PMC8014090. 2. Leijten NM, Bakker P, Spaink HP, den Hertog J, Lemeer S. Thermal Proteome Profiling in Zebrafish Reveals Effects of Napabucasin on Retinoic Acid Metabolism. Mol Cell Proteomics. 2021 Feb 13;20:100033. doi: 10.1074/mcp.RA120.002273. Epub ahead of print. PMID: 33594990; PMCID: PMC7950114.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Zhang Y, Jin Z, Zhou H, Ou X, Xu Y, Li H, Liu C, Li B. Suppression of prostate
cancer progression by cancer cell stemness inhibitor napabucasin. Cancer Med.
2016 Feb 21. doi: 10.1002/cam4.675. [Epub ahead of print] PubMed PMID: 26899963.


2: Li Y, Rogoff HA, Keates S, Gao Y, Murikipudi S, Mikule K, Leggett D, Li W,
Pardee AB, Li CJ. Suppression of cancer relapse and metastasis by inhibiting
cancer stemness. Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839-44. doi:
10.1073/pnas.1424171112. Epub 2015 Jan 20. PubMed PMID: 25605917; PubMed Central
PMCID: PMC4330785.